The HiBiT Target Cell Killing (TCK) platform, with off-the-shelf, mix-and-match components, measures four killing mechanisms for broad immunotherapy modality assessment. The post ADCs, mAbs, CAR Ts: One Bioluminescent Platform Measures Them All appeared first on GEN - Genetic Engineering and Biotechnology News .